Compare TFX & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFX | INDV |
|---|---|---|
| Founded | 1943 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.7B |
| IPO Year | 1994 | 2014 |
| Metric | TFX | INDV |
|---|---|---|
| Price | $134.51 | $37.81 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $138.75 | N/A |
| AVG Volume (30 Days) | 865.1K | ★ 2.0M |
| Earning Date | 05-07-2026 | 06-08-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 0.69 |
| Revenue | ★ $1,992,713,000.00 | $1,239,000,000.00 |
| Revenue This Year | $15.97 | N/A |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | ★ N/A | $53.49 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $100.18 | $11.08 |
| 52 Week High | $139.67 | $41.00 |
| Indicator | TFX | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 61.31 | 58.90 |
| Support Level | $102.20 | $29.71 |
| Resistance Level | $134.84 | $37.83 |
| Average True Range (ATR) | 4.18 | 1.36 |
| MACD | 0.08 | -0.32 |
| Stochastic Oscillator | 91.23 | 37.98 |
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).